Inverse association between use of broad spectrum penicllin with beta-lactamase inhibitors and prevalence of type 1 diabetes mellitus in Europe

Abstract Increasing incidence of type 1 diabetes is supposed to be induced by environmental factors. Microbiome modulated by antibiotics seems to serve as one of the environmental factors which could influence the development of T1DM. Mitochondria, as autochthonous environmental bacteria living in o...

Descripción completa

Guardado en:

Detalles Bibliográficos
Autores principales:	Gábor Ternák, Károly Berényi, Szilárd Kun, Nóra Szigeti, Tamás Decsi, Gábor Sütő, István Wittmann
Formato:	article
Lenguaje:	EN
Publicado:	Nature Portfolio 2021
Materias:	Medicine R Science Q
Acceso en línea:	https://doaj.org/article/3be5e46e824a4c3694a015295b085347
Etiquetas:	Agregar Etiqueta Sin Etiquetas, Sea el primero en etiquetar este registro!

id	oai:doaj.org-article:3be5e46e824a4c3694a015295b085347
record_format	dspace
spelling	oai:doaj.org-article:3be5e46e824a4c3694a015295b0853472021-12-02T16:46:35ZInverse association between use of broad spectrum penicllin with beta-lactamase inhibitors and prevalence of type 1 diabetes mellitus in Europe10.1038/s41598-021-96301-y2045-2322https://doaj.org/article/3be5e46e824a4c3694a015295b0853472021-08-01T00:00:00Zhttps://doi.org/10.1038/s41598-021-96301-yhttps://doaj.org/toc/2045-2322Abstract Increasing incidence of type 1 diabetes is supposed to be induced by environmental factors. Microbiome modulated by antibiotics seems to serve as one of the environmental factors which could influence the development of T1DM. Mitochondria, as autochthonous environmental bacteria living in our cells, and other bacteria share many common enzymes including beta-lactamases and it is supported by evidence that some beta-lactamase inhibitors are able to interact with counterpart enzymes. Thus, antibiotics may utilize two different pathways influencing the development of T1DM; one through modulation of microbiome and a second one via the interaction of mitochondrial enzymes. Data of consumption of penicillin (both narrow and broad spectrum) and beta-lactamase inhibitors in 30 European countries were collected from the database of the European Centre for Disease Prevention and Control. These data were correlated with the prevalence reported by the International Diabetes Federation (2019) referring to type 1 diabetes in Europe. No correlation was found between total penicillin consumption or use of broad spectrum penicillin and the prevalence of type 1 diabetes. Nevertheless, broad spectrum penicillin, in combination with beta-lactamase inhibitor, was in inverse correlation with the prevalence of type 1 diabetes (r = − 0.573, p = 0.001). On the other hand, narrow spectrum penicillin was in positive correlation with type 1 diabetes (r = 0.523, p = 0.003). Prevalence of type 1 diabetes showed an inverse correlation with the use of beta-lactamase inhibitors and a positive one with that of narrow spectrum penicillin. Such a detailed analysis has not so far been provided referring to the penicillin group. In the background of this association either microbiomal or direct mitochondrial effects can be supposed.Gábor TernákKároly BerényiSzilárd KunNóra SzigetiTamás DecsiGábor SütőIstván WittmannNature PortfolioarticleMedicineRScienceQENScientific Reports, Vol 11, Iss 1, Pp 1-9 (2021)
institution	DOAJ
collection	DOAJ
language	EN
topic	Medicine R Science Q
spellingShingle	Medicine R Science Q Gábor Ternák Károly Berényi Szilárd Kun Nóra Szigeti Tamás Decsi Gábor Sütő István Wittmann Inverse association between use of broad spectrum penicllin with beta-lactamase inhibitors and prevalence of type 1 diabetes mellitus in Europe
description	Abstract Increasing incidence of type 1 diabetes is supposed to be induced by environmental factors. Microbiome modulated by antibiotics seems to serve as one of the environmental factors which could influence the development of T1DM. Mitochondria, as autochthonous environmental bacteria living in our cells, and other bacteria share many common enzymes including beta-lactamases and it is supported by evidence that some beta-lactamase inhibitors are able to interact with counterpart enzymes. Thus, antibiotics may utilize two different pathways influencing the development of T1DM; one through modulation of microbiome and a second one via the interaction of mitochondrial enzymes. Data of consumption of penicillin (both narrow and broad spectrum) and beta-lactamase inhibitors in 30 European countries were collected from the database of the European Centre for Disease Prevention and Control. These data were correlated with the prevalence reported by the International Diabetes Federation (2019) referring to type 1 diabetes in Europe. No correlation was found between total penicillin consumption or use of broad spectrum penicillin and the prevalence of type 1 diabetes. Nevertheless, broad spectrum penicillin, in combination with beta-lactamase inhibitor, was in inverse correlation with the prevalence of type 1 diabetes (r = − 0.573, p = 0.001). On the other hand, narrow spectrum penicillin was in positive correlation with type 1 diabetes (r = 0.523, p = 0.003). Prevalence of type 1 diabetes showed an inverse correlation with the use of beta-lactamase inhibitors and a positive one with that of narrow spectrum penicillin. Such a detailed analysis has not so far been provided referring to the penicillin group. In the background of this association either microbiomal or direct mitochondrial effects can be supposed.
format	article
author	Gábor Ternák Károly Berényi Szilárd Kun Nóra Szigeti Tamás Decsi Gábor Sütő István Wittmann
author_facet	Gábor Ternák Károly Berényi Szilárd Kun Nóra Szigeti Tamás Decsi Gábor Sütő István Wittmann
author_sort	Gábor Ternák
title	Inverse association between use of broad spectrum penicllin with beta-lactamase inhibitors and prevalence of type 1 diabetes mellitus in Europe
title_short	Inverse association between use of broad spectrum penicllin with beta-lactamase inhibitors and prevalence of type 1 diabetes mellitus in Europe
title_full	Inverse association between use of broad spectrum penicllin with beta-lactamase inhibitors and prevalence of type 1 diabetes mellitus in Europe
title_fullStr	Inverse association between use of broad spectrum penicllin with beta-lactamase inhibitors and prevalence of type 1 diabetes mellitus in Europe
title_full_unstemmed	Inverse association between use of broad spectrum penicllin with beta-lactamase inhibitors and prevalence of type 1 diabetes mellitus in Europe
title_sort	inverse association between use of broad spectrum penicllin with beta-lactamase inhibitors and prevalence of type 1 diabetes mellitus in europe
publisher	Nature Portfolio
publishDate	2021
url	https://doaj.org/article/3be5e46e824a4c3694a015295b085347
work_keys_str_mv	AT gaborternak inverseassociationbetweenuseofbroadspectrumpenicllinwithbetalactamaseinhibitorsandprevalenceoftype1diabetesmellitusineurope AT karolyberenyi inverseassociationbetweenuseofbroadspectrumpenicllinwithbetalactamaseinhibitorsandprevalenceoftype1diabetesmellitusineurope AT szilardkun inverseassociationbetweenuseofbroadspectrumpenicllinwithbetalactamaseinhibitorsandprevalenceoftype1diabetesmellitusineurope AT noraszigeti inverseassociationbetweenuseofbroadspectrumpenicllinwithbetalactamaseinhibitorsandprevalenceoftype1diabetesmellitusineurope AT tamasdecsi inverseassociationbetweenuseofbroadspectrumpenicllinwithbetalactamaseinhibitorsandprevalenceoftype1diabetesmellitusineurope AT gaborsuto inverseassociationbetweenuseofbroadspectrumpenicllinwithbetalactamaseinhibitorsandprevalenceoftype1diabetesmellitusineurope AT istvanwittmann inverseassociationbetweenuseofbroadspectrumpenicllinwithbetalactamaseinhibitorsandprevalenceoftype1diabetesmellitusineurope
_version_	1718383390424563712

Inverse association between use of broad spectrum penicllin with beta-lactamase inhibitors and prevalence of type 1 diabetes mellitus in Europe

Ejemplares similares